Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmiento R, Lo Vullo S, Mariani L, Gasparini G. Morabito A, et al. Among authors: gasparini g. Breast Cancer Res Treat. 2004 Aug;86(3):249-57. doi: 10.1023/B:BREA.0000036898.45123.e9. Breast Cancer Res Treat. 2004. PMID: 15567941 Clinical Trial.
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G. Morabito A, et al. Among authors: gasparini g. Breast Cancer Res Treat. 2003 Mar;78(1):29-36. doi: 10.1023/a:1022197109592. Breast Cancer Res Treat. 2003. PMID: 12611454 Clinical Trial.
Prognostic and predictive indicators in operable breast cancer.
Morabito A, Magnani E, Gion M, Sarmiento R, Capaccetti B, Longo R, Gattuso D, Gasparini G. Morabito A, et al. Among authors: gasparini g. Clin Breast Cancer. 2003 Feb;3(6):381-90. doi: 10.3816/CBC.2003.n.002. Clin Breast Cancer. 2003. PMID: 12636883 Review.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D. Gasparini G, et al. Breast Cancer Res Treat. 2007 Mar;101(3):355-65. doi: 10.1007/s10549-006-9306-9. Epub 2006 Jul 19. Breast Cancer Res Treat. 2007. PMID: 16850247 Clinical Trial.
Antiangiogenic agents.
Stani SC, Capaccetti B, Bonginelli P, Sarmiento R, De Sio L, Fanelli M, Gasparini G. Stani SC, et al. Among authors: gasparini g. Suppl Tumori. 2002 Jul-Aug;1(4):S39-43. Suppl Tumori. 2002. PMID: 12415816 Review. No abstract available.
900 results